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Commonly used as a treatment for Type II diabetes,
sulfonylureas (SUs) stimulate insulin secretion from
pancreatic b cells by binding to sulfonylurea recep-
tors. Recently, SUs have been shown to also activate
exchange protein directly activated by cAMP 2
(Epac2), however, little is known about this molecular
action. Using biosensor imaging and biochemical
analysis, we show that SUs activate Epac2 and the
downstream signaling via direct binding to Epac2.
We further identify R447 of Epac2 to be critically
involved in SU binding. This distinct binding site
from cAMP points to a newmode of allosteric activa-
tion of Epac2.We also show that SUs selectively acti-
vate Epac2 isoform, but not the closely related
Epac1, further establishing SUs as a new class of iso-
form-selective enzyme activators.
INTRODUCTION
Type II diabetes is a rising epidemic worldwide, and is character-
ized by insulin resistance, insulin deficiency, or both (Zimmet
et al., 2001). In the case of insulin resistance, cells fail to respond
properly to insulin, the hormone primarily responsible for stimu-
lating the uptake of glucose from the blood stream into systemic
tissues, whereas insulin deficiency is a condition in which insuf-
ficient insulin is produced by the pancreas (Lin and Sun, 2010).
Accordingly, one of the strategies for the treatment of Type II
diabetes is to stimulate insulin secretion from pancreatic b cells
thereby alleviating the symptoms of diabetes (DeFronzo, 1999).
This was first accomplished orally with the class of drugs known
as sulfonylureas (SUs) (Duhault and Lavielle, 1991) that remain
a frequently prescribed class of drugs to treat Type II diabetes
(Hanefeld, 2007).
SUs exert their anti-diabetic effects by indirectly increasing the
cytosolic concentration of Ca2+, the molecular prerequisite for
insulin secretory vesicle fusion and release (Holz, 2004). In
a normal pancreatic b cell, glucose uptake induces the closure
of ATP-sensitive potassium channels (KATP channels), which
depolarizes the membrane, resulting in the opening of plasmaChemistry & Biology 18, 243membrane Ca2+ channels and Ca2+ influx. SUs exploit the
same signaling cascade to stimulate insulin secretion as they
trigger closure of KATP channels via direct binding to the sulfonyl-
urea receptor (SUR), a subunit of KATP channels (Ashcroft and
Rorsman, 1989). In both normal and diseased b cells, insulin
secretion is potentiated by increases in intracellular cAMP that
activates two primary effectors, cAMP-dependent protein
kinase (PKA) and Exchange protein directly activated by cAMP
(Epac) (Holz, 2004). Interestingly, recent data suggests that
SUs can also activate Epac2, leading to activation of Rap1
(Zhang et al., 2009), a well-characterized downstream target of
Epac proteins (Holz, 2004). It was further demonstrated that
Epac2/ mice treated with glucose plus SU or SU alone show
diminished insulin secretion and elevated blood glucose levels
when compared to WT mice receiving identical treatments.
These data led the authors to suggest that maximal SU-induced
insulin secretion requires binding to both SUR1 and Epac2
(Zhang et al., 2009). Although SU action via SUR1 is well charac-
terized, little is known about the interaction between SU and
Epac or the mechanisms by which SUs activate Epac2 and the
downstream signaling.
Epac proteins are cellular sensors of cAMP and function as
guanine nucleotide exchange factors for the small GTPases
Rap1 and Rap2. There exist two Epac isoforms, Epac1 and
Epac2, which have different tissue expression patterns (Holz
et al., 2006)—Epac1 is ubiquitously expressed whereas Epac2
is found at high levels in the brain, adrenal glands, and in endo-
crine tissues, including the pancreas (Kawasaki et al., 1998;
Roscioni et al., 2008). Structurally, although both contain a regu-
latory domain consisting of a disheveled, Egl-10, and pleckstrin
(DEP) domain for membrane targeting and a high affinity cAMP
binding domain (CNB-B, Kd = 2.8 mM and 1.2 mM, for Epac1
and Epac2, respectively) as well as a catalytic domain to
promote Rap1 binding and nucleotide exchange, Epac2
contains an additional N-terminal low affinity cAMP binding
domain (CNB-A, Kd = 87 mM) that Epac1 lacks (Holz et al.,
2006). Despite these differences, Epac1 and Epac2 share a great
deal of sequence similarity and have many of the same interac-
tion partners, including SUR1 in insulin secreting cells (Holz,
2004). The mechanism of activation by the endogenous agonist
cAMP is also shared between Epac1 and Epac2. In the auto-in-
hibited state of both isoforms, the regulatory domain sterically
blocks the Rap1 binding interface in the catalytic domain, and
cAMP binding induces a conformational change in the ‘‘hinge–251, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 243
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(Rehmann et al., 2006; Tsalkova et al., 2009). SUs represent
a class of novel activators of Epac2 (Zhang et al., 2009), however
several key questions remain as to whether SUs directly bind to
Epac2 (Gloerich and Bos, 2010), how the activation is accom-
plished, or whether the same activation occurs to Epac1.
In this study, we investigated SU-induced activation of Epac
by employing FRET based biosensors to monitor a series of
molecular events such as the activation of Epac and Rap1.
These FRET-based biosensors can serve as powerful tools
both for analyzing complex cellular processes in the native
context of the living cell and for assaying direct molecular inter-
actions in vitro. Combining this approach with biochemical anal-
ysis, we show that SU directly binds to and activates Epac2,
leading to activation of Rap1 and Extracellular signal Regulated
Kinase-1/2 (ERK1/2), a downstream target of Rap1. We further
identified a putative SU binding site on Epac2 and demonstrated
isoform selectivity for SU-induced activation of Epac2 over
Epac1. These findings establish SUs as a new example of
isoform-selective activating drugs that bind to a site distinct
from that of the endogenous agonist but exploit a similar confor-
mational change to activate the enzyme.
RESULTS
SUs Activate Epac2 through Direct Binding
We first examined the effect of four clinically approved SUs,
namely glibenclamide (GLB), acetohexamide (ACT), tolbutamide
(TOL), or glipizide (GLP), on the activity of Epac2 by using
a FRET-based reporter of Epac2 activation in HEK293T cells.
In this reporter, full length Epac2 is sandwiched between
Cerulean, a cyan fluorescent protein variant (Rizzo et al., 2004),
and Venus, a yellow fluorescent protein (Nagai et al., 2002)
(see Figure S1A available online). The cAMP-induced conforma-
tional change of Epac2 that accompanies its activation can be
detected as a decrease in FRET, which was depicted as an
increase in the emission ratio of cyan over yellow in Figure S1B.
In agreement with the recent finding that SUs activate Epac2 in
cells (Zhang et al., 2009), we observed an increase in cyan
over yellow emission ratio of 7.6 ± 1.3% (n = 10) (mean ± stan-
dard deviation [SD] [n = number of cells]) in cells treated with
GLB (Figures 1A and 1B; Figure S1C) and an increase of 9.3 ±
1.3% (n = 15), 5.6 ± 0.4% (n = 15), and 11.8 ± 1.6% (n = 10) in
response to ACT, TOL, and GLP, respectively (Figure S1D). After
each of the SU responses plateaued, we then added a cAMP-
elevating cocktail of the adenylyl cyclase activator forskolin
(Fsk) and general phosphodiesterase inhibitor 3-isobutyl-1-
methylxanthine (IBMX) to the cells to induce the maximal
response from the biosensor. In the case of GLB, ACT, and
TOL, this treatment generated a further emission ratio increase
of 5.2 ± 1.8%, 5.8 ± 2.0%, and 10.5 ± 1.8%, respectively (Figures
1A and 1B; Figure S1D), indicating that these compounds do
not maximally activate Epac2 at the concentrations used.
Conversely, there was no further cAMP-induced change in
FRET after GLP addition because GLP treatment alone gener-
ated amaximal response from the Epac2 biosensor (Figure S1D).
Importantly, the SU-mediated effect on the Epac2 biosensor was
not due to SU-induced cAMP accumulation because neither
GLB nor ACT induced a response from the A-kinase activity244 Chemistry & Biology 18, 243–251, February 25, 2011 ª2011 Elsereporter (AKAR), a FRET-based protein kinase A activity
biosensor that is known to detect cAMP increases with a high
sensitivity (Allen et al., 2006) (Figures S1E–S1G). Because all
four of the SUs tested activate Epac2, we chose to focus our
further studies primarily on one SU, and we decided to proceed
with GLB because this is the most clinically relevant SU.
Next, we examined the signaling events downstream of Epac2
activation in response to SU treatment, beginning with the
activation of Rap1, a signaling event that is involved in insulin
secretion (Shibasaki et al., 2007). To do this, we turned to
a FRET-based biosensor for Rap1 activation, Raichu-Rap1
(Mochizuki et al., 2001) (Figure S1H), which detects cAMP-
induced Rap1 activation in HEK293T cells only when Epac is
overexpressed, presumably because these cells do not express
enough endogenous Epac to activate Rap1 (data not shown). To
this end, we cotransfected HEK293T cells with Raichu-Rap1,
along with Epac2 tagged C-terminally with mCherry as a control
for expression. In these cells, GLB treatment caused a 4.6 ±
1.7% (n = 15) increase in yellow over cyan emission ratio of Rai-
chu-Rap1 (Figure 1C), which is consistent with the notion that
SUs act through Epac2 to activate Rap1. Subsequent treatment
of these cells with Fsk/IBMX showed a further increase in
emission ratio of 9.1 ± 3.7%, suggesting that SU treatment
does not lead to full activation of Rap1. Because similar trends
were observed in cells treated with ACT or GLP, the SU capable
of maximally activating our Epac2 biosensor, it seems that
although SUs can activate Epac2 to stimulate Rap1, this stimu-
lation is not capable of inducing maximal Rap1 activation
(Figures S1I–S1J). This finding is in contrast to the study by
Zhang et al. (2009) in which all three SUs activated Rap1, as
detected by immunoblotting assay, to levels comparable to
that induced by cAMP at the doses tested. This discrepancy
could be due to the different sensitivity of the two assays used.
Although live cell imaging is a technique to study signal trans-
duction in real time on a single cell level, it lacks the addition
amplification of signal that is often coupled to the detection
used in biochemical assays. Thus, to further examine the
signaling downstream of Epac2 activation, we analyzed the acti-
vation of ERK1/2 in response to GLB treatment at doses of 0.01,
0.1, or 5 mM by examining the level of phosphorylated ERK1/2
(pERK1/2) in HEK293T cells overexpressing Epac2-mCherry.
An increase in pERK1/2 was observed as a result of SU treat-
ment, with 5 mMGLB and 750 mMACT inducing phosphorylation
of ERK1/2 to a level comparable to that induced by cAMP (Fig-
ure 1D; Figure S1K). Together, this data shows that GLB can
activate Epac2 and initiate a signaling cascade leading to activa-
tion of Rap1 and ERK1/2.
Although there is evidence that SUs act through Epac2 to
induce insulin secretion and glucose uptake (Zhang et al.,
2009), it remains unclear if SUs directly bind to and activate
Epac2 (Gloerich and Bos, 2010). To elucidate this, we tested
the effect of SU on Epac2 in vitro. The Epac2 biosensor was puri-
fied from HEK293T cell lysates and subjected to SU treatment.
With an excitation wavelength of 435 nm for Cerulean, addition
of increasing doses of GLB led to a dose-dependent decrease
in yellow over cyan emission ratio of the Epac2 biosensor (Fig-
ure 1E), followed by a further decrease on addition of 500 mM
cAMP, consistent with what was observed in cells. This SU-
induced FRET decrease in the purified Epac2 biosensor wasvier Ltd All rights reserved
Figure 1. SUs Activate Epac2 and Downstream Signaling by Binding
Directly to Epac2
(A) HEK293T cells expressing the Epac2 biosensor were first treated with GLB
(5 mM) followed by Fsk (50 mM) and IBMX (100 mM) (n = 10). Data depicted as
mean ± standard deviation (SD).
(B) In HEK293T cells, YFP direct (far left panel) and ratio metric images of the
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Chemistry & Biology 18, 243also observedwith ACT treatment (Figure S1L) and indicates that
SU directly binds to and activates Epac2.
R447 Is Specifically Involved in SU Binding
and Activation of Epac2
With the identification of Epac2 as a direct target for SU, we set
out to identify the key residues of Epac2 involved in SU binding
and/or activation. To begin, we investigated how known SU
binding proteins bind to SUs. At the time of our study, the best
characterized SU binding protein was the plant protein acetohy-
droxy acid synthase (AHAS) that is inhibited by SU binding
(McCourt et al., 2006; Wang et al., 2009). Analysis of the crystal
structure of AHAS in complex with various SUs identifies two
residues, an arginine and a serine, in the SU binding site that
make hydrogen bonds to the core structure of the SU, and an
aspartic acid that both stabilizes the arginine and forms p stack-
ing interaction with the SU core structure (McCourt et al., 2005;
2006). We thus examined the crystal structure of Epac2 in the
auto-inhibited state for properly oriented Arg/Ser/Asp triads
that we reasoned could serve as potential SU binding sites. As
an additional criterion, we only chose those triads that were at
least partially solvent exposed for two reasons: first, the SU
binding site on AHAS is relatively exposed, and second, by
excluding buried triads, we reduce the chance of causing
misfolding of Epac2 when point mutations are introduced. We
then set out to mutate the arginine, the residue that makes the
most contacts with the SU core, of each triad to alanine.
Among the putative SU-binding triads that we identified in
Epac2, we selected four from different locations on the protein
and mutated these arginine residues to alanine—R53 in the
CNB-A domain, R447 and R466, both in the CNB-B domain
but on either side of the hinge region, and R819 in the catalytic
region (Figure S2A). These mutations were introduced into our
Epac2 biosensor and the effect of each of these point mutations
on the SU-induced conformational change was analyzed.
Specifically, we expressed each mutated biosensor in
HEK293T cells and first treated the cells with GLB to test the
effect of SU binding, followed by treatment with a cocktail of
Fsk and IBMX to ensure that introducing the point mutation
into Epac2 did not abolish its inherent ability to bind cAMP and
adopt the active conformation. If a mutation affected SU binding
but did not affect Epac2 folding or cAMP-induced conforma-
tional change, we would expect it to cause a reduction in SUEpac2 biosensor before GLB addition (middle left panel), after GLB addition
(middle right panel), and after Fsk/IBMX addition (far right panel). Cooler colors
correspond to higher FRET and warmer colors correspond to lower FRET.
(C) HEK293T cells expressing Raichu-Rap1 and Epac2-mCherry show Rap1
activation after treatment with GLB (5 mM) and Fsk (50 mM) plus IBMX
(100 mM) (n = 15), data is mean ± SD.
(D) HEK293T cells expressing Epac2-mCherry were treated as indicated (Fsk +
IBMX, F/I) and cell lysates were separated by SDS-PAGE. Immunoblots (top)
are from a representative experiment, and quantification of pERK1/2 levels
over tubulin for each treatment (bottom) were plotted asmean ± standard error
of the mean (SEM), n = 3–5 individual experiments for each treatment. **p%
0.01, ***p < 1E-4 compared to control, #p < 0.05 between treatments.
(E) Emission spectrum of the Epac2 biosensor excited at 435 nm in the basal
state (-), after GLB [1 mM (C); 10 mM (:); 100 mM (;)] addition, and after
cAMP (500 mM) addition (A).
See also Figure S1.
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Figure 2. R447 Is Specifically Involved in SU Binding to and Activa-
tion of Epac2
(A) The GLB (5 mM) and cAMP (50 mMFsk plus 100 mM IBMX) responses of WT
(n = 10), D32A/R53A (n = 7), R447A (n = 12), R466A (n = 8), and R819A (n = 8)
Epac2 biosensors in HEK293T cells. Values are depicted as mean ± SD.
***p < 1E-08.
(B) Time course depicting the diminished GLB-induced response of the R447A
mutant (,) Epac2 biosensor compared to the WT (-) Epac2 biosensor.
(C) Emission spectrum of the R447A biosensor excited at 435 nm in the basal
state (-), after GLB [1 mM (C); 10 mM (:); 100 mM (;)] addition, and after
cAMP (500 mM) addition (A).
(D) Molecular docking studies identify a putative SU binding site where ACT
hydrogen bonds with R447 of Epac2 and makes Van der Waals contacts
with F374.
See also Figure S2.
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cAMP sensitivity comparable to that of WT (12.6 ± 1.2%)
(Figure 2A).
Of the four mutants that we generated, only one, R819A,
showed reduced sensitivity to cAMP with a response of 1.4 ±
0.9% (n = 8) (Figure 2A; Figure S2B), indicating that this mutation
renders Epac2 nonfunctional. Of all the triads that we studied,
this was the least solvent-exposed, and we thus suspect that
the R819A mutation may have affected Epac2 folding. Another
mutant, R53A, is present in the CNB-A domain and initially
showed variable responses to SU treatment. We thus decided
to clarify these findings by also mutating the aspartic acid in
this particular Arg/Ser/Asp triad (D32) to generate the D32A/
R53A double mutant. When compared to WT, the D32A/R53A
mutant displayed no difference in SU binding (7.4 ± 1.3%,
n = 7) or cAMPbinding (11.4 ± 1.0%) compared toWT (Figure 2A;
Figure S2B), and we consequently concluded that neither D32
nor R53 contribute to SU binding to Epac2. The third mutant in
our study, R466A, is located in the CNB-B domain of Epac2,
just on the edge of the hinge helix. Whereas R466A displayed
a slightly enhanced response to cAMP (22.1 ± 2.9%, n = 8), it
did not show reduced sensitivity to SU (7.0 ± 1.4%) (Figure 2A;
Figure S2B), indicating that R466 is not important for SU binding
to Epac2.
The fourth mutant in our study, R447A, is also located in the
CNB-B, but on the opposite side of the hinge helix to R466.
Unlike R466, when the R447A mutant biosensor was subjected
to GLB treatment, it displayed minimal change in emission ratio
(0.7 ± 0.8%, n = 12), while maintaining a cAMP-induced change
(12.1 ± 4.9%) comparable to that of WT (Figures 2A and 2B;
Figures S2B and S2C). Thus the R447A mutant displays a great
reduction in its ability to be activated by SU while maintaining its
cAMP-binding capability signifying that R447 is specifically
involved in SU-induced activation of Epac2.
The R447A mutant biosensor was also purified from HEK293T
cell lysates and subjected to SU treatment. Unlike the WT
biosensor, addition of GLB or ACT to the R447A biosensor did
not cause any decrease in yellow to cyan emission ratio with
CFP excitation (Figure 2C; Figure S2D). Thus SUs either do not
bind to the R447Amutant or do not effectively induce the confor-
mational change in the R447A mutant, consistent with the idea
that R447A is a residue critically involved in SU-induced activa-
tion of Epac2. In agreement with our cellular experiments,
a FRET decrease was observed after cAMP addition confirming
that although the R447Amutant of Epac2 cannot be activated by
SU, it maintains its ability to respond to cAMP.
To test the involvement of R447 in SU binding to Epac2, we
performedmolecular docking studies using ACT and the auto-in-
hibited conformation of Epac2. By defining a docking cube
centered on R447 and running 100 docking simulations, an
ACT binding site comprised of R447 and F374 was identified
(Figure 2D) (Morris et al., 1998; Seeliger and de Groot, 2010;
DeLano, 2002). R447 makes a strong hydrogen bond of <3 A˚
with ACT whereas F374 interacts with ACT through Van der
Waals contacts. The Van der Waals interaction between F374
and the R group off the urea group of ACT (R2) could explain
why SUs with larger R2 groups such as gliclazide (GLC) do not
activate Epac2 (Figure S2E) (Zhang et al., 2009), as such an inter-
action would unfavorable. Whereas S393 and D449 were not246 Chemistry & Biology 18, 243–251, February 25, 2011 ª2011 Elsevier Ltd All rights reserved
Figure 3. A Leucine Involved in cAMP Activation of Epac Is Also
Involved in SU-Induced Activation
(A) In HEK293T cells, the mutant biosensor carrying a L426W mutation in the
hinge region of the Epac2 (,; n = 12) shows reduced activation in response
to Iso (1 mM) and Fsk (50 mM) plus IBMX (100 mM) when compared with WT
(-; n = 6).
(B) The L426W mutant (,; n = 8) displays reduced activation in response to
GLB (5 mM) when compared to WT (-; n = 10). Data depicted as mean ± SD.
(C) The response of the L426W biosensor (open bars) 5min after SU addition is
diminished compared with WT (solid bars). ***p < 0.0005.
See also Figure S3.
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they do appear to play a critical role in positioning R447 into its
proper orientation to bind ACT via hydrogen bonding. Taken
together, the mutational analysis and molecular docking studies
suggest that R447 is necessary for direct SU binding to and acti-
vation of Epac2.
A Hinge Motion Is Important in both
cAMP- and SU-Dependent Activation of Epac2
To elucidate the molecular mechanisms by which SUs activate
Epac2,we investigatedwhetherSUsexploit thesamemechanism
to activate Epac2 as cAMP. In the aforementioned auto-inhibited
state of Epac proteins, the Rap1 binding domain in the catalytic
region is sterically blocked by the regulatory domain and this inhi-
bition is relieved by a cAMP-induced hinge motion (Rehmann
et al., 2006; Tsalkova et al., 2009). Structural studies of Epac2
identified an invariant leucine (L408 in Epac2 and L273 in Epac1)
and phenylalanine (F435 in Epac2 and F300 in Epac1) in the hinge
region as key residues in regulating the conformational change
(Rehmann et al., 2003; Tsalkova et al., 2009). Specifically, in the
inactive conformation, the relative positions of L408 and F435
prevent the hinge helix from swinging into the active conforma-
tion. cAMP binding, however, induces a structural rearrangement
in Epac2 that alters the position of the leucine relative to the
phenylalanine, thus permitting the hinge helix to shift into the
active conformation. It has been shown that a L273W mutant of
Epac1 displays a reduced ability to promote Rap1 nucleotide
exchange, although its cAMP binding capability is retained,
presumably because the bulky tryptophan residue is sterically
blocked by F300 and the reorientation of the hinge region is unfa-
vorable (Rehmann et al., 2003). If SUs exploit a similar hinge
motion as cAMP to achieve the active conformation of Epac2,
we would expect the L408W mutant of our Epac2 biosensor to
show diminished conformational change in response to SU.
To test this hypothesis, we generated amutant biosensor con-
tainingaL426Wmutation,where L426corresponds toL408 in the
crystal structure (Table S1). As expected, in response to the
b-adrenergic receptor agonist isoproterenol (Iso) or combined
Fsk/IBMX treatment, the L426Wmutant displayed a significantly
reduced response (4.1 ± 0.9% to Fsk/IBMX, n = 12) when
compared to WT (13.6 ± 1.8% to Fsk/IBMX, n = 6) (Figure 3A).
This confirms that, as is the case in Epac1 (Rehmann et al.,
2003), a tryptophan in the equivalent position in Epac2 is too
bulky to permit the hinge motion. Notably, whereas the previous
study utilized Rap1 nucleotide exchange assays to evaluate the
effect of L273W on Epac1, this biosensor based approach
provides a direct assay for evaluating the effect of various muta-
tions on the conformational change of Epac in living cells.
We next tested the ability of SU to activate the L426W
biosensor. When stimulated with GLB, the L426W mutant
showed a diminished response of 5.0 ± 0.5% (n = 8) when
compared to the WT biosensor that generates an emission ratio
change of 7.6 ± 1.3% (n = 10) in response to this treatment
(Figures 3B and 3C). We also tested the ability of ACT and GLP
to activate this mutant and found that they both generate similar
diminished responses compared to that of WT (Figure 3C;
Figures S3A and S3B). Because there is no evidence for direct
involvement of L426 in binding to SU from our molecular docking
study, we conclude that for both cAMP- and SU-induced activa-Chemistry & Biology 18, 243tion of Epac2, a tryptophan at residue 426 is too bulky to permit
the hinge motion for Epac2 activation. This data thus suggests
that both activators pursue the same conformational path that
involves the motion of the hinge helix to activate Epac2.
SUs Selectively Activate Epac2 Isoform
Because Epac1 and Epac2 are similar in terms of domain struc-
ture and cellular targets, wewanted to test if SU can also activate
Epac1. To test the effect of SU treatment on Epac1, we used–251, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 247
Figure 4. SUs Are Selective for Epac2 Isoform
(A) The Epac2 (C; n = 10) or Epac1 (D; n = 10) biosensor was expressed in
HEK293T cells and treated with GLB (5 mM) followed by addition of Fsk
(50 mM) plus IBMX (100 mM). Data is depicted as mean ± SD.
(B) HEK293T cells expressing Epac1-mCherry were treated as indicted
and cell lysates were separated by SDS-PAGE. Representative blots are
shown (top) and a quantification of pERK1/2 over tubulin was plotted for
each treatment as mean ± SEM. n = 3–5 individual experiments per treatment.
**p < 0.01.
(C) Quantification of GLB-induced pERK1/2 levels via Epac1 (open bars)
or Epac2 (closed bars); **p < 0.01, ***p < 1E-5.
See also Figure S4.
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and Epac1 activation, ICUE1 (DiPilato et al., 2004) (Figure S4A),
which generates a FRET decrease on Epac1 activation (Fig-
ure S4B). When transfected in HEK293T cells and subjected to
GLB treatment, the Epac1 biosensor, unlike its Epac2 counter-
part, did not show a FRET decrease, suggesting that GLB is
unable to activate Epac1 (Figure 4A). After addition of Fsk/
IBMX, however, the Epac1 biosensor was maximally activated,
confirming that the Epac1 biosensor responds to cAMP and is
functional. We observed similar trends with ACT, GLP, and
TOL as well (Figures S4C–S4E) and together these data suggest
that SUs are incapable of robustly activating Epac1. Taken with
the aforementioned data that SUs can induce robust Epac2 acti-
vation (Figure 1), SUs are identified as selective activators of
Epac2 over Epac1.
We next sought to confirm SU isoform selectivity for Epac2 by
monitoring ERK1/2 phosphorylation. In contrast to what was
observed with Epac2, cells expressing Epac1-mCherry show
no GLB-induced ERK1/2 phosphorylation; they do, however,
exhibit a large increase in pERK levels in response to Fsk/
IBMX (Figure 4B). Similarly, ACT treatment did not induce
a significant increase in pERK1/2 levels (Figure S4F). This data
demonstrates that Epac1 can activate ERK1/2 in response to
cAMP, but not SU, and confirms that SUs specifically activate
Epac2 over Epac1 (Figure 4C; Figure S4G). Because the resi-
dues that we identified to make up an SU binding site on
Epac2, namely R447 and F374, are conserved in Epac1, it is
possible that the other regions of Epac2 form additional interac-
tions to facilitate SU binding, and it is these interactions, which
are not present in Epac1, that confer the SU selectivity for
Epac2 over Epac1. To test this hypothesis we used a biosensor
containing only the Epac2 CNB-B domain fused between CFP
and YFP (Epac2-camps) (Nikolaev et al., 2004) and observed
no GLB-induced conformational change (Figures S4H–S4I).
This lack of GLB-induced conformational change (Figure S4I)
suggests that although the necessary residues for SU binding
are present, they alone are not sufficient to permit SU-induced
activation of Epac2, and that other domains of the protein may
be necessary to facilitate this activation.
DISCUSSION
The stimulation of insulin secretion from pancreatic b cells by
SUs has been suggested to be mediated through two cellular
targets: SUR1 and Epac2 (Zhang et al., 2009). Whereas a direct
role for Epac2 in SU-induced insulin secretion may be disputed
by the observation that SUs are incapable of inducing insulin
secretion in SUR1/ mice (Seghers et al., 2000), it is important
to note that pancreatic islets isolated from these mice also
demonstrate impaired cAMP-mediated, PKA-independent
insulin secretion, indicative of disrupted Epac2 signaling in these
islets (Eliasson et al., 2003). Although several rationalizations for
this effect exist, one possible explanation is that in b-cells, SUR1
facilitates proper localization of Epac2 to the molecular
machinery necessary for it to exert its effect on insulin secretion
(Kang et al., 2006). Regardless of the reason, the impaired
Epac2-mediated insulin secretion in SUR1/ islets argues that
in pancreatic islets, the functions of SUR1 and Epac2 are intri-
cately linked.248 Chemistry & Biology 18, 243–251, February 25, 2011 ª2011 ElseAlthough the action of SU through SUR1 has beenwell charac-
terized, little is known about Epac2 activation by SU. Here we es-
tablished that SUs bind directly to Epac2 to activate it and its
downstream signaling components. This classifies SUs into
a group of rare, but emergent, small molecules that serve as
enzyme activators (Zorn and Wells, 2010). Enzymes are inher-
ently powerful signaling molecules because one active enzyme
is capable of activating several downstream targets, resultingvier Ltd All rights reserved
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frequently necessary to achieve at least 90% enzyme inhibition
to effectively diminish a desired biological effect, the biological
consequence of activation of an enzyme may be achieved with
as little as 10%enhancement of its activity. For this reason, small
molecule enzyme activators are important not only for their
potential therapeutic applications, but also because they can
serve as advantageous tools to establish a better understanding
of the causal relationship between different components within
a signaling pathway (Zorn and Wells, 2010). In addition, studies
of these unique activators can expand our understanding of allo-
steric activation of enzymes.
In this study, the identification of the R447-containing SU
binding site on Epac2 shows that SUs bind to Epac2 at a site
different from cAMP to activate this guanine nucleotide
exchange enzyme and downstream signaling. Of the four estab-
lished mechanisms that a small molecule can pursue to activate
a target enzyme, this mechanism is most consistent with the
Type A1 mechanism in which binding of a small molecule to an
allosteric site on a target enzyme promotes an active enzyme
conformation (Zorn and Wells, 2010). In this study, we have
shown that the SU-bound Epac2 conformation is capable of
activating Rap1 and the downstream signaling. However, it is
known that Epac2 can also stimulate insulin secretion via
Rap1-independent mechanisms (Holz, 2004), and it is possible
that Rap1-dependent and independent events may be differen-
tially regulated by the SU-bound state of Epac2. Future studies
will address the molecular discrepancy between the SU-bound
and cAMP-bound Epac2 conformations and the ability of the
SU-bound form to stimulate Rap1-independent signaling path-
ways. This information will enhance the basic understanding of
Epac2-dependent insulin secretion.
Moreover, we have found that SUs specifically activate Epac2
over Epac1. Although this was surprising given the similarities
between the Epac isoforms, Type A1 activators can often
achieve high specificity for a protein target because the allosteric
binding site that they exploit is generally not as conserved as the
enzyme active site (Zorn and Wells, 2010). Notable examples of
known Type A1 activators that can distinguish between different
enzyme isoforms include the compound SRT1720 that specifi-
cally activates SIRT1 isoform (Milne et al., 2007) and xanthenone
that potently activates angiotensin-converting enzyme 2 (ACE2)
but does not effect ACE activity (Hernandez Prada et al., 2008).
In the case of Epac2, whereas sequence alignment suggests that
R447 and F374 are homologous in Epac1, it is possible that there
are additional interactions in Epac2 that are not present in
Epac1, and these interactions are necessary for formation of
the SU-binding site. The observation that a biosensor containing
only the Epac2 CNB-B domain is not effected by SU treatment
(Figure S4I) supports the hypothesis that other domains in
Epac2 are necessary for the SU-induced activation. Future
structural studies should provide a vital comparison between
Epac1 and Epac2 to better understand the isoform selectivity
of SUs for Epac2.
Together, the findings here identify Epac2 as a direct target for
SU and reveal isoform selectivity of SU for Epac2 over Epac1. To
our knowledge, there are no other reports of isoform-selective
allosteric activators of Epac or any other GEFs. As Epac1 is
widely expressed in a variety of tissues and implicated in diverseChemistry & Biology 18, 243functions including cardiac hypertrophy and neuronal disorders
(Gloerich and Bos, 2010; Zarich, 2009), selective activation of
Epac2 without affecting Epac1 may be a more viable pharmaco-
logical tactic (Hinke, 2009). To generate more potent Epac2-
specific activators, however, it is important to understand the
molecular determinants underlying SU binding to and activation
of Epac2. Our findings that SUs bind to Epac2 at a new allosteric
site and utilize a similar hingemotion for activation that is used by
the endogenous agonist have expanded our understanding of
Epac activation as well as laid a foundation for generating new
Epac2-selective activators.
SIGNIFICANCE
Sulfonylureas (SUs), a frequently prescribed treatment for
Type II diabetes, stimulate insulin secretion from pancreatic
b cells by signaling through sulfonylurea receptors. More
recent evidence, however, also identifies exchange protein
directly activated by cAMP 2 (Epac2) as an intracellular
target of SUs, but whether this activation is achieved
through direct SU binding remains unclear. Additionally,
little is known about how molecules other than the endoge-
nous agonist, cAMP, activate Epac2. By using a FRET-based
biosensor for Epac2 activation we showed that SUs bind
directly to Epac2 to activate it. As a result, the downstream
targets Rap1 and ERK1/2 were activated in living cells. To
identify the molecular determinants of SU binding to and
activation of Epac2, we combined mutational analysis with
molecular docking studies and identified R447 in Epac2 to
be critically involved in this action. We further show that
SU-mediated Epac activation may engage the same hinge
motion as cAMP-induced activation. Although both R447
and the hinge region are conserved between Epac2 and
the closely related isoform Epac1, SU-induced activation
of Epac was found to be preferential for Epac2. Selectivity
of SUs for Epac2 over Epac1 may be therapeutically benefi-
cial as Epac1 is ubiquitously expressed and involved in
various cellular processes (Hinke, 2009). Collectively, these
studies identify SUs as a new class of isoform-selective
enzyme activators and have revealed a new mode of allo-
steric activation of Epac2. As Epac proteins emerge as crit-
ical regulators of many cAMP-dependent processes and as
new drug targets for treating diseases such as Type II dia-
betes (Gloerich and Bos, 2010), these findings should
provide a basis for the development of more effective thera-
peutic agents and for the further enhancement of our under-
standing of Epac signaling at a molecular and cellular level.
EXPERIMENTAL PROCEDURES
Gene Construction
Epac2 and Epac1 were PCR amplified and ligated into the mammalian expres-
sion vector pcDNA3.1 already containing properly oriented Cerulean and
Venus or mCherry. Epac2 mutants were generated using QuickChange
Mutagenesis.
Cellular Culture and Transfection
HEK293T were grown in Dulbecco’s modified Eagle’s medium cell culture
media supplemented with 10% fetal bovine serum at 37Cwith 5%CO2. Cells
were plated into 35-mm glass-bottom dishes for imaging and 10-cm culture–251, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 249
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phosphate.
Cellular Imaging and Analysis
Cells were imaged in Hanks’ balanced salt solution on a Zeiss Axiovert 200M
microscopewith a cooled charge-coupled device camera (MicroMAXBFT512,
Roper Scientific, Trenton, NJ) controlled by METAFLUOR software (Universal
Imaging, Downingtown, PA). Using a 420DF20 excitation filter and a 450DRLP
dichroic mirror, dual emission ratio imaging was performed using appropriate
emission filters, 475DF40 for Cerulean and 535DF25 for Venus. Cells were
treated with drug as indicated.
Western Blot
Cells were transfected for 24 hr, washedwith phosphate buffered solution, and
treated with respective drugs for 30 min. The treated cells were then lysed in
RIPA buffer, incubated on ice for 30 min and spun at 13,000 3 g at 4C for
30 min. Total protein concentration was detected by BCA assay (Pierce).
Proteins were separated on 7.5%SDS-PAGE, and transferred to nitrocellulose
membranes, which were blocked in 5% bovine serum albumin, and incubated
overnight with primary antibodies. Membranes were washed, incubated with
secondary antibody, and ECL western blotting substrate (Pierce) was used
for detection. Densitometric analysis was performed using ImageJ (NIH) and
pERK1/2 levels were normalized to tubulin levels within each sample.
All experiments were repeated three to five times.
In Vitro Fluorescence Assays
After 48 hr transfection, HEK293T cells were spun and lysed in a buffer pH 7.4
containing 50mM Tris-HCl, 100mMNaCl, 1 mMEDTA, 1mMPMSF, protease
inhibitor cocktail (Roche), and 0.2% Triton X-100 in a Dounce homogenizer.
Lysed cells were spun and 50 ml of Ni-NTA beads (QIAGEN) was added to
the supernatant. The beads were spun, washed once in buffer containing
10 mM imidazole, and eluted in buffer containing 100 mM imidazole. Purified
protein was detected by Coomassie stain (Pierce Biotechnology) and western
analysis using anti-GFP antibody (eBioscience). Fluorescence spectra of
Epac2 biosensors were measured with excitation at 435 nm before and after
addition of SU as well as cAMP. Spectra were normalized to the CFP peak
at 475 nm.
Molecular Docking
Crystal structures were viewed and images generated in Pymol v1.3 (DeLano,
2002). Molecular docking studies of ACT to Epac2 (PDB ID: 2BYV [Rehmann
et al., 2006]) were performed with AutoDock 4.2 (Seeliger and de Groot,
2010). ACT was sketched using MOE and minimized with the MMFF94x force
field in MOE (Chemical Computing Group). A docking cube of 25 A˚ was
centered on ‘‘CZ’’ atom of R447. For the 100 docking runs that were executed,
the following Lamarckian genetic algorithm parameters were set: maximum
number of energy evaluations was 2,500,000, maximum number of genera-
tions was 27,000, mutation rate of 0.02, crossover rate of 0.8, and window
size was 10 (Morris et al., 1998).SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and one table and can be
found with this article online at doi:10.1016/j.chembiol.2010.12.007.
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